The American Society of Hematology and International Consensus guidelines recommend using thrombopoietin receptor agonists (TPO-RAs) as the preferred second-line therapy for ITP patients after first -line treatment failure. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.